文献速递认知障碍与痴呆

多领域生活方式干预对轻度认知障碍的亚组分析

Multidomain Lifestyle Intervention in Mild Cognitive Impairment: Subgroup Analysis of the SUPERBRAIN-MEET Randomized Trial.
PubMed 文献 · Neurology · 2026-07-20

SUPERBRAIN-MEET随机对照试验的预设亚组分析,纳入277例60-85岁轻度认知障碍患者,评估多领域生活方式干预(MLI)的认知效果是否受社会人口学、数字 readiness、基线认知及血管风险特征影响。24周时MLI组RBANS总指数评分较对照组显著提高4.17分(95%CI 1.92-6.43),经错误发现率校正后无显著亚组交互,提示效果在各亚组中一致。

要点

  • MLI在24周显著改善MCI患者RBANS总指数评分,组间差异4.17分(95%CI 1.92-6.43)。
  • 社会人口学、数字 readiness、基线认知及血管风险特征未显著修饰MLI的认知获益。
  • 亚组分析为探索性且统计效能有限,结果需谨慎解读。

核心结论

  • MLI的认知获益在各预设亚组中一致,未受社会人口学、数字 readiness、基线认知或血管风险特征显著修饰。

研究设计与样本

  • SUPERBRAIN-MEET为24周、多中心、结果评估者盲法、平行组随机对照试验,在韩国17家医院开展。
  • 纳入60-85岁MCI成人,按1:1随机分配至MLI组或对照组;改良意向性分析纳入277例(MLI组142例,对照组135例),平均年龄72.9岁,女性占69.3%。

主要发现

  • 24周时MLI组RBANS总指数评分较对照组显著提高,组间差异4.17分(95%CI 1.92-6.43)。
  • 经错误发现率校正后,无亚组交互作用保持显著。

关键数值与推荐

  • 主要结局为基线至24周RBANS总指数评分变化。
  • 亚组基于社会人口学因素(性别、年龄、教育、居住状况)、数字 readiness(互联网接入、数字设备使用频率)、认知状态(MMSE评分)及血管风险特征(BMI、肥胖、吸烟、血压、血脂、空腹血糖、心血管合并症)定义。
  • 采用线性混合效应模型含交互项及错误发现率校正评估效应修饰。

临床怎么用

  • 结果支持技术辅助的多领域生活方式干预在MCI老年人痴呆预防中的可推广性和可扩展性。
  • 临床可考虑将MLI作为MCI患者痴呆预防的干预选项,不受社会人口学或血管风险特征限制。

局限性

  • 亚组分析为探索性,统计效能有限,结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Mild cognitive impairment (MCI) is a high-risk stage for progression to dementia. The SUPERBRAIN-MEET trial previously demonstrated cognitive benefits of a multidomain lifestyle intervention (MLI) delivered through face-to-face sessions and digital platforms. The aim of this study was to examine whether the cognitive effects of the MLI varied according to sociodemographic characteristics, digital readiness, baseline cognitive status, and vascular risk profiles, in a prespecified subgroup analysis of the SUPERBRAIN-MEET randomized controlled trial. METHODS: SUPERBRAIN-MEET was a 24-week, multicenter, outcome assessor-blinded, parallel-group randomized controlled trial conducted across 17 hospitals in South Korea. Adults aged 60-85 years with MCI were randomly assigned (1:1) to the MLI or control group. Subgroups were defined based on sociodemographic factors (sex, age, education, and living status), digital readiness (internet access, frequency of digital device use), cognitive status (MMSE score), and vascular risk profiles (body mass index [BMI], obesity status, smoking status, systolic and diastolic blood pressure, serum total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, fasting plasma glucose, and cardiovascular comorbidity). The primary outcome was the change in the repeatable battery for the assessment of neuropsychological status (RBANS) total index score from baseline to 24 weeks. Effect modification was assessed using linear mixed-effects models with interaction terms and false discovery rate correction. RESULTS: Of 300 randomized participants, 277 participants (mean age, 72.9 years; 69.3% female) were included in the modified intention-to-treat analysis (142 in the MLI group and 135 in the control group). MLI significantly improved RBANS total index scores compared with control at 24 weeks (between-group difference, 4.17 points; 95% CI 1.92-6.43). No subgroup interactions remained significant after false discovery rate correction, indicating consistent effects across subgroups. DISCUSSION: In this subgroup analysis of the SUPERBRAIN-MEET trial, the cognitive benefits of MLI were not significantly modified by sociodemographic factors, digital readiness, baseline cognitive status, or vascular risk profiles. These findings should be interpreted with caution, given the exploratory nature of subgroup analyses and limited statistical power. The results support the generalizability and scalability of technology-assisted multidomain lifestyle interventions for dementia prevention in older adults with MCI. TRIAL REGISTRATION INFORMATION: The trial was registered at ClinicalTrials.gov (NCT05023057; submitted August 20, 2021; first patient enrolled September 3, 2021; URL: clinicaltrials.gov/study/NCT05023057).

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Kim DA, Lee SM, Sun K, et al. Multidomain Lifestyle Intervention in Mild Cognitive Impairment: Subgroup Analysis of the SUPERBRAIN-MEET Randomized Trial. Neurology. 2026. PMID: 42475653. doi:10.1212/WNL.0000000000218297

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。